PHAXIAM Therapeutics (PHXM) 6-K Unaudited Interim Condensed Consolidated Statements of Financial Position

Exhibit 99.1

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Amounts in thousands of euros)

	As of
	December 31, 2016			June 30, 2017
	€			€
ASSETS
Non-current assets
Intangible assets		57			43
Property, plant and equipment, net		2,245			2,730
Other non-current financial assets		132			130
Total non-current assets		2,434			2,903
Current assets
Inventories		145			170
Trade and other receivables		218			336
Other current assets		4,524			7,348
Cash and cash equivalents		37,646			88,551
Total current assets		42,533			96,405
TOTAL ASSETS		44,967			99,307
	As of
	December 31, 2016			June 30, 2017
	€			€
LIABILITIES AND SHAREHOLDERS’ EQUITY
Shareholders’ equity
Share capital		873			1,174
Premiums related to share capital		105,090			170,159
Reserves		(48,412	)		(69,581	)
Net loss for the period		(21,913	)		(14,081	)
Total shareholders’ equity		35,638			87,671
Non-current liabilities
Long-term provisions		163			167
Financial liabilities—non-current portion		2,816			2,426
Deferred tax		3			3
Total non-current liabilities		2,982			2,596
Current liabilities
Financial liabilities—current portion		50			817
Trade and other payables		4,832			6,164
Other current liabilities		1,465			2,059
Total current liabilities		6,347			9,040
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY		44,967			99,307